Clinical Trial

Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)

Study acronym: REACH
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to demonstrate that treatment with avelumab in combination with RT-cetuximab is superior to standard of care (SOC) cisplatin-RT and/or to SOC RT-cetuximab alone in terms of progression-free survival (PFS) in front-line patients with locally advanced SCCHN.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2016-12-20; most recent amendment 2025-05-06.
Status change: Recruiting → Active, Not Recruiting 2020-11-03
Status change: Not Yet Recruiting → Recruiting 2017-12-11
Trial Details
NCT Number NCT02999087
Lead Sponsor Groupe Oncologie Radiotherapie Tete et Cou
Collaborators: UNICANCER
Conditions HNSCC
Enrollment 707 participants
Start Date 2017-09-14
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-07